The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01192295




Registration number
NCT01192295
Ethics application status
Date submitted
30/08/2010
Date registered
1/09/2010
Date last updated
18/10/2017

Titles & IDs
Public title
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
Scientific title
An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children From Ages 6 to 16 Years Old, Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioid Analgesics
Secondary ID [1] 0 0
2010-020471-23
Secondary ID [2] 0 0
OTR3001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pain 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Oxycodone HCl controlled-release tablets

Experimental: Oxycodone HCl controlled-release - Oxycodone hydrochloride (HCl) controlled-release (CR)


Treatment: Drugs: Oxycodone HCl controlled-release tablets
Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The Number of Participants With Adverse Events as a Measure of Safety. - Safety assessments consisted of reports of AEs, physical examinations, clinical laboratory test results, vital signs measurements, pulse oximetry (SpO2), and somnolence assessments. Safety variables were summarized descriptively within age group for the safety population.
Timepoint [1] 0 0
Up to 4 weeks (during the study) and 7-10 days poststudy (safety follow-up assessment).
Secondary outcome [1] 0 0
Pain Right Now Assessment by Patients Aged 6 to < 12 Years - Pain right now was assessed by patients aged 6 to <12 years using the Faces of Pain Scale-Revised (FPS-R). The FPS-R is a horizontal row of 6 faces representing pain intensity, with "no hurt" at the far left and "hurts worst" at the far right; the 6 intensities are scored as 0, 2, 4, 6, 8, or 10 (the patient was not shown the numbers associated with the faces). A score of 0 means no pain, and a 10 means very much pain. Pain right now was assessed by the patient at screening; after the first dose; and, thereafter, twice daily during the AM and PM, approximately at the time of each (morning and evening) dose of oxycodone HCl CR tablets during the study treatment.
Timepoint [1] 0 0
Baseline to week 4
Secondary outcome [2] 0 0
Pain Right Now Assessment by Patients Aged = 12 to = 16 Years - Pain right now was assessed by patients aged = 12 to = 16 years using the 100-mm visual analogue scale (VAS). The 100-mm VAS is a 100-mm line with 1 end marked "no pain" and the opposite end marked as "pain as bad as it could be." The patient was asked to make a mark on that line indicating his or her level of pain. The pain right now 100-mm VAS score was defined as the distance (in mm) from the "no pain" end to the patient's mark. The scale is measured on a 100 mm line: a 0 means no pain and bigger numbers indicate more pain. Pain right now was assessed by the patient at screening; after the first dose; and, thereafter, twice daily during the AM and PM, approximately at the time of each (morning and evening) dose of oxycodone HCl CR tablets during the study treatment.
Timepoint [2] 0 0
Baseline to week 4
Secondary outcome [3] 0 0
Use of Supplemental Pain Medication - Supplemental opioid and nonopioid pain medications were permitted during the study as deemed appropriate by the investigator. The dose of supplemental analgesic medication allowed was at the discretion of the investigator and within appropriate dose ranges for age and weight.
Timepoint [3] 0 0
Baseline to week 4
Secondary outcome [4] 0 0
Parent/ Caregiver-Assessed Global Impression of Change (PGIC) - The PGIC rating score variable was collected on a 7-point scale ranging from 1 to 7 (where 1 = very much improved; and 7 = very much worse). The PGIC is designed to assess overall satisfaction with the treatment. The number and percent of parent/caregivers reporting each category of PGIC response at the final visit was summarized for the safety population within age group.
Timepoint [4] 0 0
Baseline to week 4 or early discontinuation
Secondary outcome [5] 0 0
Parent/ Caregiver Assessed Functional Disability Inventory (FDI) for Patients Aged 6 to < 12 Years - The FDI is a validated tool used to evaluate the degree to which children have reduced physical and psychosocial functioning because of their pain difficulties in the previous 2 weeks. The FDI comprises 15 items. Responses to each item were scored using a 5-point Likert scale. The individual scores are: (0) no trouble, (1) a little trouble, (2) some trouble, (3) a lot of trouble, and (4) impossible. A total score (ranging from 0 to 60) for the 15 items was calculated, with lower scores indicating less functional disability. The FDI was performed by the parent/ caregiver.
Timepoint [5] 0 0
Baseline to week 4
Secondary outcome [6] 0 0
Parent/ Caregiver Assessed Functional Disability Inventory (FDI) for Patients Aged = 12 to = 16 Years - The FDI is a validated tool used to evaluate the degree to which children have reduced physical and psychosocial functioning because of their pain difficulties in the previous 2 weeks. The FDI comprises 15 items. Responses to each item were scored using a 5-point Likert scale. The individual scores are: (0) no trouble, (1) a little trouble, (2) some trouble, (3) a lot of trouble, and (4) impossible. A total score (ranging from 0 to 60) for the 15 items was calculated, with lower scores indicating less functional disability. The FDI was performed by the parent/ caregiver.
Timepoint [6] 0 0
Baseline to week 4
Secondary outcome [7] 0 0
Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets - Plasma concentration data were characterized for a population PK model of oxycodone hydrochloride controlled-release tablets in opioid tolerant pediatric patients. Plasma samples were collected after the first dose on day 1 (one sample 2 to 4 hours after the dose and 1 sample 4 to 6 hours after the dose with approximately 2 hours between the samples), and immediately predose (morning or evening dose) and 2 to 4 hours after that dose at visit 2 and/or visit 3; a total of 4 to 6 samples were collected.
Timepoint [7] 0 0
Day 1, week 2, and week 4

Eligibility
Key inclusion criteria
Inclusion Criteria include:

- Male and female patients aged 6 to 16 years, inclusive, who are expected to require
ongoing around-the-clock opioid treatment equivalent to at least 20-mg daily dose of
oxycodone for at least 2 weeks for management of moderate to severe (based on the
investigator's judgment) malignant or nonmalignant pain.

- Patients must be opioid tolerant, ie, have been treated with opioids for at least the
5 consecutive days prior to dosing and with at least 20 mg daily of oxycodone or the
equivalent during at least the last 48 hours prior to the start of study drug dosing
and have tolerated the therapy, as demonstrated at the start of study drug dosing.

- Patients who are currently using transdermal fentanyl should have been on the patch
for at least 3 days before removing the patch and oxycodone hydrochloride (HCl)
controlled-release (CR) treatment can only be initiated at least 18 hours following
the removal of the transdermal fentanyl patch.

- Patients must not require more than a 240-mg total daily dose of oxycodone HCl CR
tablets.

- Patients must be willing and able to swallow the oxycodone HCl CR tablets whole.

- Patients must not be currently on an investigational medication/therapy at the start
of screening or during the study.
Minimum age
6 Years
Maximum age
16 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria include:

- Female patients who are pregnant or lactating.

- Patients who are allergic to oxycodone or have a history of allergies to other opioids
(this criterion does not include patients who have experienced common opioid side
effects [eg, nausea, constipation]).

- Patients who have received epidural opioids < 2 hours prior to the first dose of study
drug or who have received epidural morphine < 12 hours prior to the first dose of
study drug.

- Patients who are contraindicated for the use of opioids.

- Patients who are contraindicated for blood sampling.

- Patients who are currently being maintained on methadone for pain.

- Patients who have any planned surgery during the course of the study, with the
exception of the placement of central or peripheral venous access devices.

- Patients who have had surgery within 5 days prior to Day 1 (day of first dose of study
drug).

- Patients who, in the investigator's opinion, have an underlying gastrointestinal
condition or other disorder that may predispose them to obstruction.

Other protocol-specific inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Delaware
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Oklahoma
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Utah
Country [21] 0 0
United States of America
State/province [21] 0 0
Virginia
Country [22] 0 0
United States of America
State/province [22] 0 0
Wisconsin
Country [23] 0 0
Greece
State/province [23] 0 0
Athens
Country [24] 0 0
Hungary
State/province [24] 0 0
Budapest
Country [25] 0 0
Israel
State/province [25] 0 0
Beersheba
Country [26] 0 0
Israel
State/province [26] 0 0
Haifa
Country [27] 0 0
Israel
State/province [27] 0 0
Jerusalem
Country [28] 0 0
Israel
State/province [28] 0 0
Peta? Tiqwa
Country [29] 0 0
Israel
State/province [29] 0 0
Ramat Gan
Country [30] 0 0
New Zealand
State/province [30] 0 0
Auckland
Country [31] 0 0
Romania
State/province [31] 0 0
Targu Mures
Country [32] 0 0
Spain
State/province [32] 0 0
Barcelona
Country [33] 0 0
United Kingdom
State/province [33] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Purdue Pharma LP
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl)
controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16 years,
inclusive, with moderate to severe malignant and/or nonmalignant pain requiring opioid
therapy.
Trial website
https://clinicaltrials.gov/show/NCT01192295
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications